Get the Stockscreener App
354.06
4.84%
16.33
After Hours:
354.50
0.44
+0.12%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $354.06, with a volume of 4.73M.
It is up +4.84% in the last 24 hours and up +7.42% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$337.73
Open:
$342.91
24h Volume:
4.73M
Relative Volume:
1.81
Market Cap:
$191.09B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
24.62
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+2.45%
1M Performance:
+7.42%
6M Performance:
+11.56%
1Y Performance:
+21.33%
1-Day Range:
$341.45
$358.46
1-Week Range:
$337.49
$358.46
52-Week Range:
$267.83
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
354.06 | 182.28B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,160.95 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
238.33 | 574.10B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
224.77 | 397.44B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.76 | 294.13B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.92 | 282.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen hires Duke research organization to save Tavneos from market removal - Seeking Alpha
Amgen taps Duke Research Institute to reevaluate disputed Tavneos data By Investing.com - Investing.com Canada
Amgen’s Repatha Diabetes Data Reframes Cardiometabolic Upside For Investors - simplywall.st
Amgen Reevaluates Tavneos Data as Medicine Faces FDA Scrutiny - Bloomberg.com
Amgen Hires Avenue Solutions for Medicare Lobbying - Legis1
Amgen Named Among World’s Most Impactful Companies 2026 by TIME - Amgen
Here is Why Amgen (AMGN) is One of the Top Large Cap Value Stocks to Buy Now - Insider Monkey
Dow's 750-Point Rally Led By Gains In Shares Of Amgen, Boeing - Moomoo
Amgen, Honeywell Share Gains Lead Dow's 265-Point Jump - Moomoo
Caterpillar, Amgen Share Gains Lead Dow's 414-Point Jump - 富途牛牛
Is Amgen Inc. (AMGN) A Good Stock To Buy Now? - Insider Monkey
Amgen Inc Stock (AMGN) Moved Up by 3.35% on Jun 11: What Signal Does It Send? - TradingKey
Dow Rallies 288 Points On Gains For Amgen, Caterpillar Shares - 富途牛牛
Renaissance Group LLC Has $36.95 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Townsquare Capital LLC Sells 3,602 Shares of Amgen Inc. $AMGN - MarketBeat
Janney Montgomery Scott LLC Has $141.09 Million Stake in Amgen Inc. $AMGN - MarketBeat
ING Groep NV Buys New Shares in Amgen Inc. $AMGN - MarketBeat
Gilpin Wealth Management LLC Takes Position in Amgen Inc. $AMGN - MarketBeat
Capital Wealth Planning LLC Raises Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Amgen Can't Amend Petition To Address Potential Double Tax - Law360
Amgen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
AMGN Maintains by Morgan Stanley -- Price Target Raised to $340 - GuruFocus
What Amgen CFO Told Goldman Sachs About the IRS, MariTide, and Why the Stock May Be Worth $467 - TIKR.com
Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market? - Yahoo Finance
Motley Fool Asset Management LLC Increases Position in Amgen Inc. $AMGN - MarketBeat
Amgen eyes 2026 'springboard' as growth drugs offset patent pressure - MSN
Morgan Stanley raises Amgen stock price target on obesity drug potential - Investing.com Canada
Amgen Inc. stock (US0311621009): focus on weight-loss and cancer pipeline after latest earnings - AD HOC NEWS
Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure - MarketBeat
Amgen Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Is It Too Late To Consider Amgen (AMGN) After Its Strong Multi Year Share Price Run? - Yahoo Finance
Amgen Inc. $AMGN Shares Purchased by LPL Financial LLC - MarketBeat
Franklin Resources Inc. Has $712.09 Million Stake in Amgen Inc. $AMGN - MarketBeat
Cerity Partners LLC Has $134.82 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
AMGN|Amgen Inc|Price:349.076|Chg%:11.35 - TradingKey
Goldman Sachs Trims Amgen (AMGN) Valuation but Sticks with Buy Rating - Yahoo Finance
Amgen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Amgen stock (US0311621009): FDA filing and pipeline momentum in focus - AD HOC NEWS
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Why Amgen Inc (AMGN) Is Set to Outperform the Market: Insights i - GuruFocus
AMGN DCF Analysis: Intrinsic Value $292 vs Price $350 - GuruFocus
Can MariTide Save Amgen Stock From Its Fading Blockbusters? - Trefis
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
O Shaughnessy Asset Management LLC Buys 27,035 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. stock (US0311621009): Weight-loss pipeline and Horizon deal keep biotech in focus - AD HOC NEWS
Hilton Head Capital Partners LLC Purchases Shares of 3,798 Amgen Inc. $AMGN - MarketBeat
Los Angeles Capital Management LLC Decreases Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Bought by Erste Asset Management GmbH - MarketBeat
Brandywine Global Investment Management LLC Has $140 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Unveils Promising Data on Diabetes at ADA Conferenc - GuruFocus
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):